
LifeBTK Trial: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Audible BleedingShow Notes
In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space. Guest: Dr. DeRubertis, is the Principal Investigator of the LIFE-BTK trial. He is the Chief of the Division of Vascular & Endovascular Surgery at New York-Presbyterian and Weill Cornell Medicine in New York City. Audible Bleeding Team Dr. Jamila Hedhliis a general surgery resident at the University of Illinois. Anh Dang, (@QuynhAnh_Dang), is a fourth year medical student at the University of Pennsylvania. Dr. Naveed A. Rahman, (@naveedrahmanmd), is a Vascular Surgery Fellow at the University of Maryland.
References: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease (LIFE-BTK).
Advances in Endovascular Treatment of CLTI: Insights From the LIFE-BTK Trial.
Diversity, Equity, and Inclusion in the LIFE-BTK Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions in Patients with Chronic Limb-Threatening Ischemia, VIVA 2024.
Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial (YUKON).
Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease (DESTINY).
A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease (ACHILLES).
Sex Differences in Outcomes Following Endovascular Treatment for Symptomatic Peripheral Artery Disease: An Analysis From the K- VIS ELLA Registry.
Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial.
Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).
The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.
More from Audible Bleeding
Audible Bleeding editor Wen Kawaji (@WenKawaji) is joined by Dr. Danielle Garcia, Dr. Robert Meyers, JVS editor Dr. Duncan (@ADuncanVasc), and JVS-VL editor Dr. Ruth Bush to discuss some of our favorite articles in the JVS family of journals.
Jacob Soucy (@JacobWSoucy) hosts an inside look at a timely and thought-provoking editorial published in The Vascular Specialist, the official news magazine of the Society for Vascular Surgery. In this episode, we explore the introduction of preference signaling to the integrated vascular surgery match through the lens of the editorial "This Signal Brings Noise." The discussion examines whether signaling addresses problems that exist within the vascular surgery match, how signals may influence interview selection, and the potential unintended consequences of introducing artificial scarcity into an already highly successful match process. Jacob speaks with Dr. Malachi G. Sheahan III about the motivation behind the piece, the problems preference signaling is intended to solve, how applicants and programs may approach the new system, and why signaling may turn the application process into a strategic game. They also discuss application review, virtual versus in-person interviews, the role of program reputation and mentorship in applicant decision-making, and what the vascular surgery community should watch as signaling is implemented for the first time.
Audible Bleeding Editor and vascular surgery fellow Sasank Kalipatnapu (@ksasank) is joined by James Martinson, a practicing general surgeon with an interest in vascular surgery, currently serving as the ship's surgeon for the USS John F. Kennedy aircraft carrier; JVS editor Dr. Audra Duncan (@ADuncanVasc); and JVS-CIT editor Dr. Matthew Smeds (@MattSmeds) to discuss two great articles in the JVS family of journals. Articles: Part 1: The association between multimorbidity and arteriovenous fistula creation outcomes (Wei and Woo)
Audible Bleeding Editor and vascular surgery fellow Richa Kalsi (@KalsiMD) is joined by James Martinson, practicing general surgeon with an interest in vascular surgery currently serving as the ship's surgeon for the USS Harry S Truman aircraft carrier and Langford Green (@langfordgreen_), research fellow at the Center for Vascular Research at the University of Maryland currently applying to medical school, JVS editor Dr. Audra Duncan (@ADuncanVasc), and JVS-VI editor Dr. Anahita Dua (@AnahitaDua) to discuss two great articles in the JVS family of journals. Articles: Part 1: Open bypass versus endovascular therapy in chronic limb-threatening ischemia patients with prior endovascular attempts (Hamouda & Malas)
Welcome back to the Audible Bleeding Series: Landmark Papers in Vascular Surgery. In this episode, Audible Bleeding editor John Culhane and co-host Dr. Jesse Columbo are joined by our guests, Dr. David Stone, Dr. Salvatore Scali, and Dr. Anders Wanhainen to unpack one of the longest-running debates in aortic surgery: when (and whether) to repair an abdominal aortic aneurysm. We'll start our episode with the open-repair era and the two trials that set the basis for the 5.5 cm threshold—UKSAT and ADAM—then move into the early EVAR years with PIVOTAL and CAESAR, which asked whether fixing smaller aneurysms with endovascular technology could do better. Finally, we'll look at how modern screening programs, improved medical therapy, and current guidelines have reshaped the practical decisions we make for these patients every day.